

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BioDlink International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

**CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER,
AUTHORISED REPRESENTATIVE AND COMPOSITION OF
BOARD COMMITTEE**

RE-DESIGNATION OF NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of BioDlink International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, Mr. Fu, Shan (“**Mr. Fu**”) has been re-designated from a non-executive director to an executive director of the Company with effect from 11 October 2025 (the “**Re-designation**”) and is responsible for leading and overseeing the management and development of the Group. Following the Re-designation, Mr. Fu remains as chairperson of the Board, chairperson of the Nomination Committee and chairperson of the Strategy and ESG Committee of the Company.

Mr. Fu will enter into a new letter of appointment with the Company in relation to his re-designation as an executive director of the Company for a fixed term ending on 11 March 2028. His directorship will be subject to retirement by rotation and re-election pursuant to the articles of association of the Company. Mr. Fu is entitled to an annual director’s fee as an executive director of the Company. The remuneration of Mr. Fu shall be determined by the Board with reference to his contributions, experience and relevant duties and responsibilities within the Company. Notwithstanding the foregoing, to demonstrate his support for the Company, Mr. Fu has voluntarily agreed to receive a nominal annual director’s fee of HK\$1 for his service as an executive director during his term of office.

Biographical details of Mr. Fu

Mr. Fu, Shan (付山, former Chinese name “傅山”), aged 57, joined the Group on 19 January 2016 as a non-executive director and was appointed the chairperson of the Board on 28 September 2018. In addition, he holds directorship in subsidiaries of the Company.

Mr. Fu has since October 2013 been a managing partner, a co-CEO and the Greater China CEO of Vivo Capital LLC, which is an investment management firm that primarily invests in the field of biotechnology and healthcare. Vivo Capital LLC is deemed to have an interest in the Company’s issued share capital through its controlled corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and is a substantial shareholder of the Company. A non-executive director of the Company, Dr. Liu, Weidong, is also currently serving as managing director of Vivo Capital LLC.

Between June 2008 and October 2013, Mr. Fu worked as a senior managing director in the Beijing branch of Blackstone (Shanghai) Equity Investment Management Company Limited. He has been a non-executive director of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (Hong Kong Stock Exchange: 2291) since June 2021 and a director of Sinovac Biotech Ltd. (NASDAQ: SVA) since July 2018. Mr. Fu was also appointed as a director of VISEN Pharmaceuticals (Hong Kong Stock Exchange: 2561, which became listed on the Main Board of the Hong Kong Stock Exchange in March 2025) in November 2018, and was re-designated as a non-executive director in March 2021. He was also a director of Genetron Holdings Limited (NASDAQ: GTH) from June 2021 to March 2024 and a non-executive director of InnoCare Pharma Limited (Hong Kong Stock Exchange: 9969; Shanghai Stock Exchange STAR Market: 688428) from February 2018 to March 2023.

Mr. Fu obtained a master’s degree in history and a bachelor’s degree in history, both from Peking University in Beijing, the PRC, in July 1991 and July 1988, respectively.

Save as disclosed above, as at the date of this announcement, Mr. Fu:

- (i) does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”)) of the Company;
- (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and
- (iii) does not have, and is not deemed to have, any interests in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Fu has confirmed that, save as disclosed above, there is no other matter concerning the Re-designation that is required to be brought to the attention of the shareholders of the Company, nor is there any other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

RESIGNATION OF DIRECTORS AND CHIEF EXECUTIVE OFFICER AND CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board announces the following change of directors and chief executive of the Company with effect from 11 October 2025:

- (i) due to personal reasons, Dr. Liu, Jun (“**Dr. Liu**”) has resigned as an executive director, chief executive officer, chief scientific officer, and a member of the Strategy and ESG Committee of the Company; and
- (ii) due to personal reasons, Ms. Yeh-Huang, Chun-Ying (“**Ms. Yeh-Huang**”) has resigned as a non-executive director, vice chairperson of the Board, and a member of the Strategy and ESG Committee of the Company.

In addition, each of Dr. Liu and Ms. Yeh-Huang will also retire from all subsidiaries of the Company of all directorships and (if applicable) executive positions.

Dr. Liu and Ms. Yeh-Huang will be engaged as strategic consultants of the Group following their resignations.

Each of Dr. Liu and Ms. Yeh-Huang has confirmed that, as at the date of this announcement, he/she has no disagreement with the Board and he/she is not aware of matters relating to his/her cessation of the above-mentioned positions that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

CHANGE OF AUTHORISED REPRESENTATIVE

Following the cessation of directorship of Dr. Liu, Mr. Fu has been appointed as an authorised representative of the Company as required under Rule 3.05 of the Listing Rules in replacement of Dr. Liu with effect from 11 October 2025.

By order of the Board
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 13 October 2025

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.